SDS-PAGE
(SDS PAGE for Icrucumab)
anti-Human Icrucumab Monoclonal Antibody | anti-FLT1 antibody
Research Grade Icrucumab
Gene Names
FLT1; FLT; FLT-1; VEGFR1; VEGFR-1
Reactivity
Human
Purity
>95%; Protein A or G purified from cell culture supernatant.
Synonyms
Icrucumab, Antibody; Research Grade Icrucumab; 18F1; IMC-18F1; LY3012212; FLT1; Vascular endothelial growth factor receptor 1; VEGFR1; Vascular permeability factor receptor; FRT; Tyrosine-protein kinase receptor FLT; VEGFR-1; FLT; FLT-1; Tyrosine-protein kinase FRT; Fms-like tyrosine kinase 1; anti-FLT1 antibody
Reactivity
Human
Clonality
Monoclonal
Isotype
IgG1-kappa
Purity/Purification
>95%; Protein A or G purified from cell culture supernatant.
Form/Format
Liquid. PBS buffer, pH7.4
Concentration
2.49 mg/ml (varies by lot)
Host Species
Human
CAS
1024603-92-6
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
Preparation and Storage
Store at -20 degree C 12 months. Store at -80 degree C long term.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
SDS-PAGE
(SDS PAGE for Icrucumab)
SDS-PAGE
(SDS PAGE for Icrucumab)
Bioactivity
(Detects Human FLT1 in direct ELISAs.)
Bioactivity
(Detects Human FLT1 in direct ELISAs.)
Product Categories/Family for anti-FLT1 antibody
References
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy, PMID: 27733377
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer, PMID: 28220020
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial, PMID: 26926681
Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials, PMID: 34229563
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2, PMID: 21046523
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer, PMID: 28220020
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial, PMID: 26926681
Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials, PMID: 34229563
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2, PMID: 21046523
NCBI and Uniprot Product Information
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Accession #
Molecular Weight
150,769 Da
NCBI Official Full Name
vascular endothelial growth factor receptor 1 isoform 2
NCBI Official Synonym Full Names
fms-related tyrosine kinase 1
NCBI Official Symbol
FLT1
NCBI Official Synonym Symbols
FLT; FLT-1; VEGFR1; VEGFR-1
NCBI Protein Information
vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular
UniProt Protein Name
Vascular endothelial growth factor receptor 1
UniProt Gene Name
FLT1
UniProt Synonym Gene Names
FLT; FRT; VEGFR1; VEGFR-1; FLT-1; FLT
UniProt Entry Name
VGFR1_HUMAN
Similar Products
Product Notes
The FLT1 flt1 (Catalog #AAA120056) is an Antibody and is intended for research purposes only. The product is available for immediate purchase. The Research Grade Icrucumab reacts with Human and may cross-react with other species as described in the data sheet. It is sometimes possible for the material contained within the vial of "Icrucumab, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.